Skip to main content

Table 1 Demographic data and basic characteristics of ESRD patients and healthy control subjects

From: Heart rhythm complexity as predictors for the prognosis of end-stage renal disease patients undergoing hemodialysis

Variables

ESRD patients

(n = 51)

Healthy control subjects

(n = 51)

P value

Male/female

30/21

24/27

0.321

Age (year)

57 (52–67)

58 (52–65)

0.859

Height (cm)

169 (162–177)

168 (159–175)

0.451

Weight (kg)

82 (72–97)

70 (64–83)

< 0.001

BMI (kg/m2)

29.37 (24.39–33.47)

25.30 (23.62–27.48)

< 0.001

BP_SYS (mmHg)

143 (127–169)

120 (118–140)

< 0.001

BP_DIA (mmHg)

73 (65–88)

80 (75–80)

0.227

Smoking, n (%)

6 (11.8)

20 (39.2)

0.003

Diabetes Mellitus, n(%)

32 (62.7%)

N.A

N.A

Hypertension, n(%)

51 (100%)

N.A

N.A

LVEF (%)

60 (55–65)

N.A

N.A

Duration of dialysis (year)

2 (3–6)

N.A

N.A

Kt/V

1.42 (1.24–1.61)

N.A

N.A

URR (%)

74 (70–79)

N.A

N.A

nPCR

0.85 (0.72–0.97)

N.A

N.A

Sodium (mEq/dL)

139 (137–141)

N.A

N.A

Potassium (mEq/dL)

5.1 (4.4–5.4)

N.A

N.A

Chloride (mEq/dL)

100 (97–103)

N.A

N.A

Bicarbonite (mEq/dL)

26 (22–29)

N.A

N.A

Blood Urea Nitrogen (mg/dL)

58 (45–72)

N.A

N.A

Creatinine (mg/dL)

8.3 (6.6–10.4)

N.A

N.A

Glucose (mg/dL)

106 (88–137)

N.A

N.A

Calcium (mg/dL)

8.7 (8.3–9.2)

N.A

N.A

Phosphate (mg/dL)

5.3 (4.3–6.2)

N.A

N.A

Calcium Phosphate Product

44.7 (35.6–51.1)

N.A

N.A

Albumin (g/dL)

4.0 (3.8–4.2)

N.A

N.A

Hemoglobin (g/dL)

11.7 (11.0–12.3)

N.A

N.A

Hematocrit (%)

36.0 (34.0–38.0)

N.A

N.A

β-blocker, n (%)

34 (66.7)

N.A

N.A

CCB, n (%)

25 (49.0)

N.A

N.A

ACEI, n (%)

15 (29.4)

N.A

N.A

  1. ESRD end-stage renal disease, BMI body mass index, BP_SYS systolic blood pressure, BP_DIA diastolic blood pressure, N.A not applicable, LVEF left ventricular ejection fraction, URR urea reduction ratio, nPCR normalized protein catabolic rate, CCB calcium channel blocker, ACEI angiotensin-converting-enzyme inhibitor